Inventor · disambiguated record
Tibor Keler
Also filed as: KELER TIBOR · KELER TIBOR P
40 granted patents·24 pending applications·2,794 citations·filing 1996–2025
98Inventor score
Files withCELLDEX THERAPEUTICS INC25KELER TIBOR10MEDAREX INC10BRISTOL MYERS SQUIBB CO6CELDARA MEDICAL LLC2
Top patents by PatentIndex Score
64 records- 0199US8017114B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2009·Granted Sep 13, 2011·199 cites·33 claims
- 0299US7605238B2Human CTLA-4 antibodies and their usesMEDAREX INC·Filed 2001·Granted Oct 20, 2009·353 cites·32 claims
- 0399US6984720B1Human CTLA-4 antibodiesMEDAREX INC·Filed 2000·Granted Jan 10, 2006·897 cites·14 claims
- 0499US5922845ATherapeutic multispecific compounds comprised of anti-Fcα receptor antibodiesMEDAREX INC·Filed 1996·Granted Jul 13, 1999·448 cites·24 claims
- 0598US8784815B2Human CTLA-4 antibodies and their usesKORMAN ALAN J·Filed 2012·Granted Jul 22, 2014·40 cites·29 claims
- 0698US8318916B2Human CTLA-4 antibodies and their usesKORMAN ALAN J·Filed 2011·Granted Nov 27, 2012·49 cites·38 claims
- 0796US9169325B2Antibodies that bind human CD27 and uses thereofKELER TIBOR·Filed 2011·Granted Oct 27, 2015·64 cites·19 claims
- 0896US7456264B2Human monoclonal antibodies against Bacillus anthracis protective antigenMEDAREX INC·Filed 2004·Granted Nov 25, 2008·88 cites·32 claims
- 0996US7452535B2Methods of treatment using CTLA-4 antibodiesMEDAREX INC·Filed 2003·Granted Nov 18, 2008·70 cites·18 claims
- 1096US6303755B1Therapeutic multispecific compounds comprised of anti-FCA receptor antibodiesMEDAREX INC·Filed 1999·Granted Oct 16, 2001·116 cites·17 claims
- 1195US7387776B2Human monoclonal antibodies against CD30MEDAREX INC·Filed 2003·Granted Jun 17, 2008·70 cites·15 claims
- 1294US10668152B2Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatmentBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jun 2, 2020·7 cites·21 claims
- 1394US10633444B2Agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2019·Granted Apr 28, 2020·12 cites·8 claims
- 1493US10392442B2Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatmentBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Aug 27, 2019·6 cites·20 claims
- 1593US8142778B2Methods of treatment using CTLA-4 antibodiesDAVIS THOMAS ANDREW·Filed 2008·Granted Mar 27, 2012·25 cites·75 claims
- 1693US6365161B1Therapeutic compounds comprised of anti-FC receptor binding agentsMEDAREX INC·Filed 1999·Granted Apr 2, 2002·113 cites·20 claims
- 1792US6682928B2Cells expressing anti-Fc receptor binding componentsMEDAREX INC·Filed 1998·Granted Jan 27, 2004·89 cites·24 claims
- 1891US8236318B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)KELER TIBOR·Filed 2008·Granted Aug 7, 2012·17 cites·19 claims
- 1990US11332537B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2021·Granted May 17, 2022·1 cites·26 claims
- 2090US10941201B2Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodiesCELLDEX THERAPEUTICS INC·Filed 2020·Granted Mar 9, 2021·2 cites·17 claims
- 2189US9259459B2Antibody vaccine conjugates and uses thereforKELER TIBOR·Filed 2004·Granted Feb 16, 2016·21 cites·14 claims
- 2287US11965031B2Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatmentBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Apr 23, 2024·1 cites·18 claims
- 2387US2024360235A1Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatmentBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2486US2025115663A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2585US11180566B2Antibodies that bind human CD27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2015·Granted Nov 23, 2021·4 cites·7 claims
- 2685US7560534B2Molecular conjugates comprising human monoclonal antibodies to dendritic cellsCELLDEX RES CORP·Filed 2001·Granted Jul 14, 2009·26 cites·8 claims
- 2785US2025346671A1Anti-pd-l1 antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2884US6193966B1Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodiesMEDERAX INC·Filed 1997·Granted Feb 27, 2001·48 cites·29 claims
- 2982US10865244B2Nucleic acids encoding agonistic antibodies that bind CD40CELLDEX THERAPEUTICS INC·Filed 2017·Granted Dec 15, 2020·1 cites·11 claims
- 3081US8362214B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)CELLDEX THERAPEUTICS INC·Filed 2009·Granted Jan 29, 2013·3 cites·11 claims
- 3181US8088377B2Human monoclonal antibodies against CD30KELER TIBOR·Filed 2008·Granted Jan 3, 2012·4 cites·10 claims
- 3281US7563876B2Human monoclonal antibodies to dendritic cellsCELLDEX THERAPEUTICS INC·Filed 2001·Granted Jul 21, 2009·11 cites·1 claims
- 3379US8586720B2Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)KELER TIBOR·Filed 2012·Granted Nov 19, 2013·3 cites·6 claims
- 3478US8318165B2Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP)KELER TIBOR·Filed 2007·Granted Nov 27, 2012·2 cites·25 claims
- 3576US2022324990A1Anti-cd27 and anti-pd-l1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3676US2025154274A1Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatmentBRISTOL MYERS SQUIBB CO·Filed 2025·Application pending·0 cites
- 3775US8142790B2Methods of using molecular conjugates comprising monoclonal antibodies to dendritic cellsDEO YASHWANT M·Filed 2008·Granted Mar 27, 2012·2 cites·8 claims
- 3875US2025059291A1Cd27 agonistsCELLDEX THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3972US11541076B2Chimeric antigen receptors targeting TIM-1CELDARA MEDICAL LLC·Filed 2018·Granted Jan 3, 2023·2 cites·20 claims
- 4072US8404820B2Human monoclonal antibodies against Bacillus anthracis protective antigenKELER TIBOR·Filed 2008·Granted Mar 26, 2013·0 cites·39 claims
- 4172US2014234331A1Human ctla-4 antibodies and their usesMEDAREX LLC·Filed 2014·Application pending·0 cites
- 4271US11459393B2Anti-CD27 and anti-PD-L1 antibodies and bispecific constructsCELLDEX THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·0 cites·7 claims
- 4371US2020024355A1Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatmentBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 4471US2019119384A1Human ctla-4 antibodies and their usesSQUIBB & SONS LLC·Filed 2018·Application pending·0 cites
- 4571US2021147538A1Agonistic antibodies that bind cd40CELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4670US2022227877A1Antibodies that bind human cd27 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4764US12297266B2Agonistic antibodies that bind human CD40 and uses thereofCELLDEX THERAPEUTICS INC·Filed 2017·Granted May 13, 2025·0 cites·19 claims
- 4863US7316812B2Cells expressing anti-Fc receptor binding componentsCELLDEX THERAPEUTICS INC·Filed 2004·Granted Jan 8, 2008·0 cites·25 claims
- 4963US2016257753A1Human ctla-4 antibodies and their usesSQUIBB & SONS LLC·Filed 2016·Application pending·0 cites
- 5062US2009324622A1Antibody vaccine conjugates and uses thereforKELER TIBOR·Filed 2009·Application pending·0 cites
Showing the top 50 of 64 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Tibor Keler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →